Kaleido Biosciences, Inc. (OTCPK: KLDO)
Health Care · Pharmaceuticals · US
$0.00
+9900.00% today · 0.0% 1Y
Kaleido Biosciences, Inc. (OTCPK: KLDO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.26K and employs 76 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.35.
Tweenvest scores Kaleido Biosciences, Inc. across four factors: quality 23/100, value 47/100. Its strongest factor is value.
KLDO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.26K
- Revenue (TTM)
- $1.10M
- P/E
- —
- EPS
- -2.16
- Dividend yield
- —
- Beta (5Y)
- 40.03
- 52-week high
- $0.35
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 42.62M
- Employees
- 76
- Next earnings
- —
About Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.
- ISIN
- US4833471000
- Founded
- 2015
- Listed since
- Feb 28, 2019
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.